Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

March 12, 2024 updated by: Acibadem University
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Study Type

Observational

Enrollment (Actual)

2197

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Acibadem University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This retrospective study examined adults with acute respiratory tract infections in Istanbul, Turkey. Patients admitted between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID) underwent multiplex PCR testing for various respiratory viruses, with a focus on human metapneumovirus. The study aimed to assess the prevalence of HMPV infection in adults and its potential change after the COVID-19 pandemic.

Description

Inclusion Criteria:

  • Adults >18 years
  • Patients with acute respiratory tract infection symptoms
  • Patients who underwent multiplex PCR testing for respiratory viruses

Exclusion Criteria:

  • Patients for whom no respiratory viral panel test was conducted

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pre-COVID period
January 2016 to January 2020
Other: Observation
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Post-COVID period
January 2021 to September 2023
Other: Observation
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic
Time Frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of HMPV with other respiratory viruses in adults
Time Frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Acibadem University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2023

Primary Completion (Actual)

December 30, 2023

Study Completion (Actual)

January 30, 2024

Study Registration Dates

First Submitted

March 12, 2024

First Submitted That Met QC Criteria

March 12, 2024

First Posted (Actual)

March 13, 2024

Study Record Updates

Last Update Posted (Actual)

March 13, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-20/687

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe